NIH grants IDT Biologika 10-year contract for vaccines and biologics manufacturing

IDT Biologika plan to fulfill the NIAID contract from its production sites in Dessau-Rosslau, Germany, and Rockville, Maryland. (IDT Biologika)

IDT Biologika has won a 10-year contract worth up to $80 million from the NIH’s National Institute of Allergy and Infectious Diseases to make vaccines and biologics for infectious diseases.

The so-called Indefinite Quantity, Indefinite Delivery contract means IDT will stay on call during the contract period as NIAID hammers out the exact content and quantity of each individual project along the way.